Core Viewpoint - Yiming Oncology (01541) has terminated its licensing agreement with Axion Bio, Inc., regaining global development and commercialization rights for two core anti-cancer drugs, IMM2510 and IMM27M, while retaining the previously received $35 million upfront and milestone payments [1] Group 1: Agreement Termination - The collaboration with Axion was initially established on August 1, 2024, granting Axion exclusive rights for the development and commercialization of IMM2510 and IMM27M outside Greater China [1] - The termination agreement allows Axion limited rights to gradually conclude its related clinical development activities [1] Group 2: Drug Details - IMM2510 is a bispecific molecule targeting VEGF/PD-L1, utilizing mAb-Trap structure to inhibit tumor angiogenesis and activate immune cells, creating an anti-tumor synergistic effect [1] - IMM27M is a next-generation CTLA-4 monoclonal antibody with enhanced ADCC activity, capable of eliminating immunosuppressive regulatory T cells in the tumor microenvironment, thereby strengthening T cell anti-tumor responses [1] Group 3: Future Development - Yiming Oncology expresses confidence in the therapeutic potential of both drugs and plans to accelerate their clinical development process [1]
收回全球权利：宜明昂科终止合作重掌两款抗癌新药，3500万美元款项已落袋